Author's posts
FDA approves two sickle cell therapies, including the first CRISPR medicine
The therapies offer hope for a long-overlooked genetic illness that can cause excruciating pain and cut decades off people’s lives.
Covid is here to stay. How will we know when it stops being special?
For some people, covid will always be high risk. Others wonder when — or if — we can stop treating the coronavirus differently from other common viruses.
First RSV antibody treatment to protect all infants approved in the U.S.
Regulators approved an RSV antibody treatment for infants that provides vaccine-like protection over the course of a single winter respiratory virus season.
Gene editing helped crack a 100-year-old mystery about cancer
Research using CRISPR gene editing revealed that scientists from more than a century ago were right: extra chromosomes inside cancer cells help drive tumors.
FDA advisers recommend updating the coronavirus vaccine to target XBB
FDA advisers voted Thursday to recommend that the coronavirus shot be updated for the fall to match the XBB variants that are now dominating globally.
He defied Alzheimer’s for two decades. Scientists want to know how.
Researchers have identified a rare gene mutation that may have helped protect a Colombian man from developing dementia.
What’s in the RSV vaccine, its side effects and when you can get one
The first RSV vaccine was approved this week for use in older adults. Here’s what to know about its efficacy, side effects, expected availability and more.
First vaccine targeting RSV wins FDA approval. More are coming.
The shot will be used to protect against respiratory syncytial virus in older adults — a turning point in the six-decade-long vaccine effort.
His sickle cell disease brought agony. Gene therapy is bringing hope.
The first gene therapies for this debilitating disease will be reviewed by regulators this year, potentially sparking a health-care revolution.
Fighting for costly drugs: ‘I never know when it’s going to end’
The stories Post readers told revealed the personal dimensions of a policy issue. The common thread was that the treatments they needed were expensive, and health insurance raised barriers to getting them.
